Seek peaks at 206 nm and get up to 200x the sensitivity of monitoring at 280 nm...



# ...with the new Uvicord S UV monitor

Sensitivity is increased up to 200x for proteins when you monitor at 206 nm with LKB's new Uvicord<sup>®</sup> S UV-monitor. This unique instrument will detect non-aromatic peptides, polysaccharides, nucleotides, lipids and steroids as well as proteins. And, naturally, you can also monitor at 254 or 280 nm.

Enhanced versatility has required no compromise in stability. Quite the contrary. Sophisticated optics and solid state circuitry provide outstanding linearity. And you can monitor simultaneously at high and low sensitivities.

Unlike others, the new Uvicord S UV-monitor is contained in a single small case which mounts easily on a fraction collector or ring stand. And its low price matches its small size.

Now available in HPLC version too!

LKB Instruments Inc. 12221 Parklawn Drive, Rockville, Maryland 20852 301: 881-2510 Circle No. 351 on Readers' Service Card 80A-312

### LETTERS

## **New Recombinant DNA Guidelines**

The statement that "All gene splicing experiments with E. coli K12 may now be conducted in minimal (P1) containment" (News and Comment, 15 Feb., p. 745) is not correct. The revised National Institutes of Health (NIH) Guidelines for Recombinant DNA Research, as promulgated on 29 January 1980, continue to prohibit certain experiments using E. coli K-12 and continue to exempt others from the guidelines. Still other experiments are permitted at P1 containment, but only when an EK1 host-vector system is used, "(i.e., (a) the host shall not contain conjunction-proficient plasmids or generalized transducing phages, and (b) lambda or lambdoid bacteriophages or non-conjugative plasmids shall be used as vectors)." The September 1979 proposal of the NIH Recombinant DNA Advisory Committee was not accepted in toto. The NIH Director rejected an exempt status for such experiments and required a more conservative review procedure for "any experiment in which there is a deliberate attempt to have the E. coli K-12 efficiently express any gene coding for a eukaryotic protein.'

BERNARD TALBOT

Office of the Director, National Institutes of Health, Bethesda, Maryland 20205

# **Caffeine** Study

Michael Jacobson (Letters, 18 Jan., p. 258) quotes a paper by our team in support of his assertion that caffeine is teratogenic (1). This statement is somewhat overstretching our conclusions.

Our study compared the frequency of various environmental, including dietary, factors in a group of 202 mothers (cases) of newborn children with birth defects and in a group of 175 mothers (control) of normal children. Average coffee intake, during pregnancy, as reported by the mothers after delivery, was one factor that showed a statistically significant (P < .05) difference between the two groups. This difference was particularly marked for heavy coffee consumption, defined as 8 cups or more per day. Heavy coffee drinkers were represented by 22 percent of the case group versus 12 percent in the control group.

While we considered this observation worth publishing, our conclusions were deliberately cautious: "The data presented do not permit us to conclude a direct relation between coffee consumption and birth defects. . . . A longitudinal study could further clarify the issue."

The reason for caution is that a number of factors, methodological or others, could be at work to produce these results. They include testing for multiple associations, which increases the chance of finding spurious ones, and indirect association of coffee drinking with birth defects through other unidentified factors.

Retrospective epidemiological studies are useful for generating or validating hypotheses. These, however, must be independently repeated before conclusions are made. Until additional ongoing studies on the relation between coffee drinking and birth defects are completed, we consider that the statement by Jacobson that "caffeine is teratogenic" is, at least as far as reference is made to our study, premature.

M. F. LECHAT, I. BORLÉE A. BOUCKAERT, C. MISSON École de Santé Publique, Catholic University of Louvain, B-1200 Brussels, Belgium

#### References

1. I. Borlée, Louvain Med. 97, 279 (1978).

### **Sea Turtle Conservation**

The generally excellent article "Experts gather to talk turtle" (News and Comment, 21 Dec. 1979, p. 1383) contains errors and omissions concerning restrictions on trade in sea turtles and products derived therefrom.

First, the author incorrectly asserts that "the United States recently added farmed turtle products to the forbidden list in CITES [Convention on International Trade in Endangered Species]." The green sea turtle was added to Appendix I (the most protected category) of CITES in 1976. This action was done by agreement of the parties to CITES and not unilaterally by the United States.

Normally, all commercial trade in Appendix I species is prohibited under CITES. However, Article VII of CITES permits limited commercial trade in specimens of Appendix I species that are "bred in captivity." CITES itself does not define the term "bred in captivity," however, and before 1979, there was no agreed upon interpretation among the parties. At the 1979 meeting of the CITES parties, a uniform interpretation was adopted which limits the term to the offspring of parents that mated in captiv-

ity, provided that the breeding herd is managed in a way that has been shown to be reliably capable of protecting at least two successive generations in captivity. This uniform interpretation was likewise made by agreement of the parties and not unilaterally by the United States. Since a judge of the U.S. District Court for the District of Columbia has recently found (1) that "a significant percentage of the [Cavman Turtle Farm's] . . . recent hatchlings were not born of parents which had mated on the farm'' (1, p. 15) and that "it may be premature to determine that the breeding cycle at Cayman Turtle Farm can be completed from farm laid egg to farm laid egg" (1, p. 15), it is clear that many of the turtles the farm now markets fail to qualify as "bred in captivity."

Second, the author notes that most conservationists believe commercial mariculture will further jeopardize wild turtle stocks, whereas farm owner Judith Mittag holds out the possibility that farm turtles could be used for restocking the wild. Not mentioned is the fact that the same judge found that evidence in the voluminous administrative record compiled over 4 years by the Secretaries of the Interior and of Commerce was "more than ample" to support their conclusion that "the survival of wild sea turtles would be threatened by either the formation of additional turtle farms or by illegal poaching" (1, p. 12). The Cayman Turtle Farm has not appealed that finding, although it has appealed the single issue of whether the Endangered Species Act is applicable at all to its turtles. In fact, while the turtle farm owners are saying their turtles may one day restock the wild, the farm is arguing to the U.S. Court of Appeals in its appellate brief (2) that their turtles "have no connection with the wild turtles roaming the oceans" and are, in fact, "domesticated" (2, p. 8).

Michael J. Bean


Wildlife Program, Environmental Defense Fund, Washington, D.C. 20036

#### References

- "Cayman Turtle Farm, Ltd. vs. Andrus et al. vs. Environmental Defense Fund, Inc. et al. Memorandum opinion" (Civil Action No. 78-1661, U.S. District Court for the District of Columbia, Washington, D.C., 29 May 1979).
  "Cayman Turtle Farm, Ltd. vs. Cecil D. Andrus Searctory. Dependence of the Interior et al.
- "Cayman Turtle Farm, Ltd. vs. Cecil D. Andrus, Secretary, Department of the Interior et al. Appellants brief" (Case No. 79-2031, U.S. Court of Appeals for the District of Columbia, Washington, D.C., 1979).

Erratum: In the article "The Leopolds: A family of naturalists" (News and Comment, 7 Mar., p. 1051), the correct title of the Sierra Club book by Charles Steinhacker and Susan Flader which was cited in the footnote on page 1052, third column, is *The Sand Country of Aldo Leopold*.

# High, wise and handsome



# The MultiRac fraction collector

LKB's new MultiRac<sup>™</sup> fraction collector is a real space saver. You can see that reservoir, column, pump, monitor and recorder can all mount on it easily. And you can keep adding decks to take as much more equipment as you want.

The new LKB fraction collector is smart too. It will collect from microliters to liters, adjust fraction size automatically according to OD, stop all flow as the head traverses, and on command will channel all void volume to waste.

Its good looks go well beneath the surface: solid state electronics, rugged materials of construction and a clear, bright, unambiguous LED display all make for an instrument that's safe, dependable and easy to use.

Contact LKB today for full details.



LKB Instruments Inc. 12221 Parklawn Drive Rockville, MD 20852 301: 881-2510 Telex: 8-9682

Circle No. 352 on Readers' Service Card

81A-313